Measuring Analgesic Interventions

January 31, 2023 updated by: Julia Finkel

Developing a Method to Objectively Measure Analgesic Interventions: A Pilot Study

It is generally recognized that pain assessment and management especially in newborns, children and other nonverbal populations is an unmet need. According to the American Medical Association, "the pediatric population is at risk of inadequate pain management, with age-related factors affecting pain management in children. Children are often given minimal or no analgesia for procedures that would routinely be treated aggressively in adults. Although much is now known about pain management in children, it has not been widely or effectively translated into routine clinical practice". These two factors combine to emphasize the necessity for an objective tool to quantify pain and monitor the effectiveness of analgesia, especially during treatments. Further, it is reported that many patients require a combination of treatments, and it is often necessary to test a variety of treatments before the personal match for treatment is found. The method in place to change the care on a subjective basis is difficult, time consuming, and not easily individualized. This pilot study is part of an ongoing effort to develop a method to objectively assess response to specific analgesic interventions. It specifically aims to discern the impact of analgesic interventions on sensory nerve fiber sensitivity in a diverse patient population.

Study Overview

Status

Recruiting

Conditions

Study Type

Observational

Enrollment (Anticipated)

120

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • District of Columbia
      • Washington, District of Columbia, United States, 20010
        • Recruiting
        • Children's National Health System
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

7 years to 21 years (ADULT, CHILD)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients who are receiving pharmacological or non-pharmacological analgesic interventions as part of their regularly occurring clinical treatment.

Description

Inclusion Criteria:

  1. The subject is 7 to 21 years of age
  2. The subject is receiving an analgesic intervention in the Children's National Medical Center Pain Clinic
  3. The subject is willing and able to provide written informed assent/parental consent to the study participation.

Exclusion Criteria:

  1. Eye pathology precluding pupillometry
  2. Patients who are actively using opioids (history of use acceptable). Rationale: opioids constrict the pupil, and therefore concomitant opioid use would bias our results.
  3. Subjects who are or may be pregnant

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Local Anesthetics
Lidocaine
N-methyl-D-aspartate Antagonists
Ketamine
SNRIs
Duloxetine
Alpha-2 adrenergic agonists
Dexmedetomidine
Oral Analgesics
NSAIDs, acetaminophen
Non-pharmacologic interventions
Acupuncture

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pupillary Reflex Dilation (PRD) Area under Curve (AUC)
Time Frame: 0, 15, 30, 45, 60, 90, 120, 180 minutes
The changes that occur in PRD AUC as a response to an analgesic intervention will be investigated. The differences are calculated by comparing the parameters from before the intervention to after the intervention.
0, 15, 30, 45, 60, 90, 120, 180 minutes

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pupillary Light Reflex (PLR) Latency
Time Frame: 0, 15, 30, 45, 60, 90, 120, 180 minutes
The changes that occur in PLR Latency as a response to an analgesic intervention will be investigated. The differences are calculated by comparing the parameters from before the intervention to after the intervention.
0, 15, 30, 45, 60, 90, 120, 180 minutes
Pupillary Light Reflex (PLR) Amplitude
Time Frame: 0, 15, 30, 45, 60, 90, 120, 180 minutes
The changes that occur in PLR Amplitude as a response to an analgesic intervention will be investigated. The differences are calculated by comparing the parameters from before the intervention to after the intervention.
0, 15, 30, 45, 60, 90, 120, 180 minutes
Pupillary Light Reflex (PLR) Recovery Time
Time Frame: 0, 15, 30, 45, 60, 90, 120, 180 minutes
The changes that occur in PLR Recovery Time as a response to an analgesic intervention will be investigated. The differences are calculated by comparing the parameters from before the intervention to after the intervention.
0, 15, 30, 45, 60, 90, 120, 180 minutes
Pupillary Reflex Dilation (PRD) Amplitude
Time Frame: 0, 15, 30, 45, 60, 90, 120, 180 minutes
The changes that occur in PRD amplitude as a response to an analgesic intervention will be investigated. The differences are calculated by comparing the parameters from before the intervention to after the intervention.
0, 15, 30, 45, 60, 90, 120, 180 minutes

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

October 29, 2018

Primary Completion (ANTICIPATED)

September 1, 2023

Study Completion (ANTICIPATED)

December 1, 2023

Study Registration Dates

First Submitted

October 31, 2018

First Submitted That Met QC Criteria

January 3, 2019

First Posted (ACTUAL)

January 7, 2019

Study Record Updates

Last Update Posted (ACTUAL)

February 1, 2023

Last Update Submitted That Met QC Criteria

January 31, 2023

Last Verified

January 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • 9586

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pain

3
Subscribe